How should I evaluate and manage persistent urinary urgency and frequency after stopping risperidone (6 months ago), escitalopram (Lexapro) and trazodone, given that trials of antimuscarinic agents (oxybutynin, solifenacin) and β‑3 agonists (mirabegron, vibegron) provided no relief?

Evaluation and Management of Refractory Urinary Symptoms After Medication Discontinuation

You need a comprehensive urologic evaluation to rule out non-OAB causes of your persistent symptoms, followed by consideration of minimally invasive therapies, since you have failed both antimuscarinic and β3-agonist pharmacotherapy. 1

Immediate Diagnostic Considerations

Your clinical picture is complex because you recently discontinued escitalopram and trazodone (both can cause urinary retention), yet you're experiencing urgency and frequency rather than retention. 2 However, the timing suggests your symptoms may not be simple overactive bladder (OAB):

• Risperidone discontinuation (6 months ago): Antipsychotics can affect bladder function, but 6 months is typically sufficient for resolution of medication effects
• Recent SSRI/trazodone discontinuation: Escitalopram has been associated with acute urinary retention 2, so stopping it should theoretically improve symptoms, not cause urgency/frequency
• Failed standard pharmacotherapy: You've already tried both major drug classes (antimuscarinics and β3-agonists) without benefit 1

Essential Workup Required

Before proceeding with additional therapy, you need:

• Post-void residual (PVR) measurement: Critical to exclude urinary retention masquerading as frequency 1, 3
• Urinalysis and urine culture: Rule out infection or other bladder pathology
• Voiding diary (3-day minimum): Quantify actual frequency, urgency episodes, and voided volumes 1
• Consider urodynamic studies: Particularly important since you failed standard therapy—may reveal detrusor overactivity, bladder outlet obstruction, or other pathology 1, 3

Treatment Algorithm for Refractory OAB

Step 1: Combination Pharmacotherapy (If Not Yet Tried)

Since monotherapy failed, the 2024 AUA/SUFU guidelines support combining therapies: 1

• Mirabegron + behavioral therapy: Add structured bladder training, timed voiding, and fluid management 1
• Consider combination pharmacotherapy: Mirabegron plus solifenacin has demonstrated superior efficacy compared to monotherapy with acceptable safety 4, though this requires careful monitoring for urinary retention given your medication history

Important caveat: Combination therapy with antimuscarinics should be used cautiously given your history of multiple CNS medications and the dementia risk associated with chronic antimuscarinic use 1

Step 2: Minimally Invasive Therapies

The 2024 AUA/SUFU guidelines explicitly state that minimally invasive procedures may be offered to patients who have failed pharmacotherapy. 1 Your options include:

• Percutaneous tibial nerve stimulation (PTNS): Non-surgical neuromodulation option
• Sacral neuromodulation: More invasive but highly effective for refractory OAB
• Intradetrusor onabotulinumtoxinA (Botox): Effective but carries risk of urinary retention requiring intermittent catheterization 1

Step 3: Rule Out Alternative Diagnoses

Your lack of response to standard therapy raises concern for:

• Bladder outlet obstruction (especially if male): Would explain frequency/urgency and poor response to OAB medications 1, 3
• Interstitial cystitis/bladder pain syndrome: May present similarly to OAB but requires different management
• Medication-induced bladder dysfunction: Though you've stopped the offending agents, residual effects or withdrawal phenomena are possible 2

Critical Pitfalls to Avoid

• Do not continue ineffective pharmacotherapy indefinitely: The guidelines emphasize discontinuing therapies that show no improvement 1
• Avoid nutraceuticals/supplements: There is insufficient evidence to support their use in OAB 1
• Do not assume this is simple OAB: Your refractory nature and complex medication history warrant thorough evaluation before empiric treatment escalation
• Monitor for urinary retention: Given your recent discontinuation of medications associated with retention, adding antimuscarinics could precipitate acute retention 1, 3

Specific Next Steps

1. Schedule urologic evaluation within 1-2 weeks with voiding diary and symptom questionnaire completed 1
2. Measure PVR immediately to exclude retention 1, 3
3. If PVR is normal and infection ruled out: Consider trial of combination therapy (behavioral + pharmacologic) for 4-8 weeks 1
4. If no improvement by 8 weeks: Proceed to minimally invasive therapy consultation 1

The 2024 AUA/SUFU guidelines emphasize that treatment failure with standard pharmacotherapy should prompt consideration of advanced therapies rather than continued medication trials. 1 Your case particularly warrants urodynamic evaluation given the atypical presentation and medication history. 1, 3